Latest Production News

Blue Star Helium has wrapped up its 2025 Galactica drilling campaign with strong results from six wells, setting the stage for commercial helium production in the second half of 2025.

Cygnus Metals has reported impressive high-grade assay results from its Golden Eye prospect in Quebec, confirming multiple mineralised zones and setting the stage for an initial resource estimate.

Strategic Energy Resources has sold its South Cobar Project to Australian Gold & Copper for $400,000 cash plus a capped production royalty, maintaining exposure while funding new exploration.

Renegade Exploration Limited reports impressive high-grade gold rock chip results from its newly acquired Caisson Project in Nevada’s Walker Lane Trend, highlighting strong exploration potential.

GTI Energy’s recent scoping study highlights promising economics for its Lo Herma uranium project in Wyoming, prompting plans for expanded drilling in 2025 to upgrade and grow its resource base.

Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.

Blue Star Helium reports robust natural flow rates and high helium concentration from its State 9 well at the Galactica project, signaling a promising step toward commercial production.

Theta Gold Mines has landed a US$35 million loan from South Africa’s Industrial Development Corporation, marking a key funding milestone for its TGME Underground Gold Mine Project.

Pure Foods Tasmania has raised $100,000 through a share placement and appointed directors to new operational roles aimed at driving sales growth and improving cost efficiency.

AnteoTech Ltd has completed a strategic review that refocuses its business on commercialising existing products, delivering $1.6 million in annual cost savings and expanding its sales pipeline in battery and life sciences markets.

Opyl Limited unveils a bold strategic pivot to enhance its AI-driven drug discovery platform, leveraging a vast proprietary dataset and leadership upgrades to redefine clinical trial innovation.

Optiscan Imaging Ltd has launched InSpecta™, a cutting-edge microscopic imaging device tailored for veterinary medicine, marking its strategic entry into a booming $12 billion US market. The device promises to revolutionize diagnostics and treatment for companion animals with real-time, non-invasive imaging.